Christine Parseghian, MD (@parseghianc) 's Twitter Profile
Christine Parseghian, MD

@parseghianc

Gastrointestinal Medical Oncologist at UT MD Anderson Cancer Center specializing in translational and clinical research in colorectal cancer. Tweets are my own.

ID: 1003486253294260226

calendar_today04-06-2018 03:59:01

47 Tweet

494 Followers

95 Following

Christine Parseghian, MD (@parseghianc) 's Twitter Profile Photo

Colorectal cancer is being diagnosed in a greater number of patients younger than 50 than ever before. Get your colonoscopies at age 45 per new guidelines and PREVENT this deadly disease! #coloncancer #prevention #cancer x.com/coloncancertas…

Cancer Cell (@cancer_cell) 's Twitter Profile Photo

Bardelli & co. investigate the radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer patients. ow.ly/gMwZ30kTqCY

Bardelli & co. investigate the radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer patients. ow.ly/gMwZ30kTqCY
Van Morris, MD (@vanmorrismd) 's Twitter Profile Photo

Excited to see the FDA approve nivo + ipi for MSI-High #crcsm. Congrats to the MD Anderson Cancer Center team that led this great work!! Have seen this combo work wonders in my patients with #colorectalcancer!!. news.bms.com/press-release/…

Van Morris, MD (@vanmorrismd) 's Twitter Profile Photo

So exciting to see BRAF/EGFR/MEK combo get #breakthrough designation by FDA for #BRAF mut #colorectalcancer. MAJOR advance for aggressive #crcsm subtype. Happy MD Anderson Cancer Center participated on this important study. Congrats Scott Kopetz & @ArrayBiopharma! bit.ly/2MfzRgG

Christine Parseghian, MD (@parseghianc) 's Twitter Profile Photo

My mentor, Scott Kopetz, sharing exciting updated results from the BEACON study finding no OS benefit with triplet regimen of enco + cetux + bini vs enco + cetux alone.

My mentor, <a href="/skopetz/">Scott Kopetz</a>, sharing exciting updated results from the BEACON study finding no OS benefit with triplet regimen of enco + cetux + bini vs enco + cetux alone.
Christine Parseghian, MD (@parseghianc) 's Twitter Profile Photo

Words cannot express the impact Dr. V had on her patients and colleagues. She was a beautiful physician and a loving mother. I will forever be grateful for her mentorship and guidance. Rest In Peace, Dr. V. You will be deeply missed.

Christine Parseghian, MD (@parseghianc) 's Twitter Profile Photo

Inspiring stories like this, and incredible and brave patients like ⁦Ben Terry⁩ keep me fighting every day against this terrible disease. #fightcrc ⁦MD Anderson Cancer Center⁩ kplctv.com/2022/11/05/met…

Kristin Alfaro (@alfaro_kristin) 's Twitter Profile Photo

Use of serial ctDNA in metastatic #CRC to refine patient selection, reduce toxicity from chemotherapy & evaluate emerging resistance mechanisms that may lead the way to novel therapeutic strategies. doi.org/10.1158/1078-0… Christine Parseghian, MD Scott Kopetz MD Anderson Cancer Center #INTERCEPT

Scott Kopetz (@skopetz) 's Twitter Profile Photo

🎉⭐️Major implications for understanding CRC biology & rechallenge studies! Resistance Mechanisms to Anti-EGFR Therapy in RAS/RAF Wildtype Colorectal Cancer Vary by Regimen & Line of Therapy pubmed.ncbi.nlm.nih.gov/?term=36351210 ParseghianC DrJasonWillis VanMorrisMD skopetz MDAndersonNews

Christine Parseghian, MD (@parseghianc) 's Twitter Profile Photo

Had the honor of co-chairing and presenting about novel therapeutics in colorectal cancer this weekend at the ESMO - Eur. Oncology conference in Barcelona! So many exciting advances, but so much left to do! MD Anderson Cancer Center Fight Colorectal Cancer #ESMO2024

Had the honor of co-chairing and presenting about novel therapeutics in colorectal cancer this weekend at the <a href="/myESMO/">ESMO - Eur. Oncology</a> conference in Barcelona! So many exciting advances, but so much left to do! <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> <a href="/FightCRC/">Fight Colorectal Cancer</a> #ESMO2024
Christine Parseghian, MD (@parseghianc) 's Twitter Profile Photo

BREAKWATER Ph3 showing an incredible improvement in ORR by 21% and doubling of the duration of response with the addition of FOLFOX to enco+cetux in BRAFV600E MT CRC. 👏🏻🙌🏻 Congrats to my forever mentor Scott Kopetz for changing the standard of care in 1L CRC!!#ASCOGI25 Fight Colorectal Cancer

BREAKWATER Ph3 showing an incredible improvement in ORR by 21% and doubling of the duration of response with the addition of FOLFOX to enco+cetux in BRAFV600E MT CRC. 👏🏻🙌🏻 Congrats to my forever mentor <a href="/skopetz/">Scott Kopetz</a> for changing the standard of care in 1L CRC!!#ASCOGI25 <a href="/FightCRC/">Fight Colorectal Cancer</a>
Dr. Cathy Eng (@cathyengmd) 's Twitter Profile Photo

What a way to close ASCO #ASCOGI25! Have an informal gathering of friends to celebrate everyone’s achievements! #promotions #leadership #research CONGRATS 👏 👏 Christine Parseghian, MD Van Morris, MD Arvind Dasari, MD, MS with my forever friends Dr. David Fogelman and the AMAZING Lara Robinson, MS.

What a way to close <a href="/ASCO/">ASCO</a> #ASCOGI25!  Have an informal gathering of friends to celebrate everyone’s achievements!  #promotions #leadership #research CONGRATS 👏 👏 <a href="/ParseghianC/">Christine Parseghian, MD</a> <a href="/VanMorrisMD/">Van Morris, MD</a> <a href="/adasarimd/">Arvind Dasari, MD, MS</a> with my forever friends Dr. David Fogelman and the AMAZING <a href="/LaraLRobinson/">Lara Robinson, MS</a>.
Christine Parseghian, MD (@parseghianc) 's Twitter Profile Photo

The incidence of young-onset colorectal cancer is frighteningly increasing over the last few decades. I share a few reasons in this interview, while telling the story of a fearless fighter patient of mine, graciously sharing his story. MD Anderson Cancer Center #CRC healthline.com/health-news/ea…

MD Anderson Cancer Center (@mdandersonnews) 's Twitter Profile Photo

What are the most provoking and practice-changing studies being presented in colorectal and anal cancer at #ASCO25? Our Dr. Christine Parseghian discussed BREAKWATER, CheckMate 8HW, and CODEBREAK 101 in the Highlights of the Day I session. Christine Parseghian, MD ASCO #EndCancer

What are the most provoking and practice-changing studies being presented in colorectal and anal cancer at #ASCO25? Our Dr. Christine Parseghian discussed BREAKWATER, CheckMate 8HW, and CODEBREAK 101 in the Highlights of the Day I session. <a href="/ParseghianC/">Christine Parseghian, MD</a> <a href="/ASCO/">ASCO</a> #EndCancer
Dr Joseph McCollom DO (@realbowtiedoc) 's Twitter Profile Photo

Dr Christine Parseghian, MD with a beautiful summary after her #crcsm trials for #BoA25 about the #future of our field including more #biomarker 🎯 therapies, tumor #plasticity and overcoming #resistance and universal #molecular testing #GIonc #BestofASCO OncoAlert🚨 #OncoAlertAF

Dr <a href="/ParseghianC/">Christine Parseghian, MD</a> with a beautiful summary after her #crcsm trials for #BoA25 about the #future of our field including more #biomarker 🎯 therapies, tumor #plasticity and overcoming #resistance and universal #molecular testing #GIonc #BestofASCO 

<a href="/OncoAlert/">OncoAlert</a>🚨
#OncoAlertAF